Pacific Biosciences of California, Inc. (PACB)
Pacific Biosciences Of California, Inc. May Have Violated Securities Laws And Shareholders Are Invited By The Schall Law Firm To Join An Investigation
LOS ANGELES, CA / ACCESSWIRE / September 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosciences of California, Inc. ("PacBio" or "the Company") (NASDAQ:PACB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Requests Investor Participation In An Inquiry Into Pacific Biosciences Of California Inc For Possible Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / September 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosciences of California, Inc. ("PacBio" or "the Company") (NASDAQ:PACB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Pacific Biosciences of California (PACB) Surpasses Market Returns: Some Facts Worth Knowing
Pacific Biosciences of California (PACB) closed at $1.81 in the latest trading session, marking a +0.56% move from the prior day.
Pacific Biosciences Of California, Inc. May Have Violated Securities Regulations And Affected Shareholders Can Help The Schall Law Firm Investigate
LOS ANGELES, CA / ACCESSWIRE / September 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosciences of California, Inc. ("PacBio" or "the Company") (NASDAQ:PACB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
PacBio Stock Drops After Singapore Collaboration for HiFi Sequencing
PACB's HiFi sequencing powers the HiFi Consortium's global effort to enhance the diagnosis and treatment of subfertility and recurrent pregnancy loss.
A Securities Fraud Inquiry Has Been Launched Into Pacific Biosciences Of California Inc And The Schall Law Firm Invites Stakeholders To Take Part
LOS ANGELES, CA / ACCESSWIRE / September 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosciences of California, Inc. ("PacBio" or "the Company") (NASDAQ:PACB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now
PacBio's (PACB) strong product demand and continued focus on R&D raise optimism about the stock.
PacBio's Stock Up on Munster Deal for Male Infertility Research
PACB collaborates with the University Hospital of Munster, using Revio HiFi sequencing to advance research on male infertility and rare diseases in Germany and globally.
Investors Are Encouraged To Assist The Schall Law Firm Investigate Whether Pacific Biosciences Of California, Inc. Violated Securities Laws
LOS ANGELES, CA / ACCESSWIRE / September 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosciences of California, Inc. ("PacBio" or "the Company") (NASDAQ:PACB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Pacific Biosciences Of California Inc May Have Defrauded The Public And The Schall Law Firm Urges Stockholders To Help With An Inquiry
LOS ANGELES, CA / ACCESSWIRE / September 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosciences of California, Inc. ("PacBio" or "the Company") (NASDAQ:PACB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Pacific Biosciences Of California Inc May Have Defrauded Shareholders And Those With Losses Should Partake In The Schall Law Firm's Inquiry
LOS ANGELES, CA / ACCESSWIRE / September 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosciences of California, Inc. ("PacBio" or "the Company") (NASDAQ:PACB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Investors Are Encouraged To Join The Schall Law Firm In An Investigation Into Pacific Biosciences Of California, Inc.'s Possible Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / September 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Biosciences of California, Inc. ("PacBio" or "the Company") (NASDAQ:PACB) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
